Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 121 articles:
HTML format



Single Articles


    March 2021
  1. JIANG Y, Martin J, Alkadhimi M, Shigemori K, et al
    Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model.
    Br J Cancer. 2021 Mar 19. pii: 10.1038/s41416-021-01296.
    PubMed     Abstract available


  2. RAKAEE M, Kilvaer TK, Jamaly S, Berg T, et al
    Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01307.
    PubMed     Abstract available


    February 2021
  3. ROSENTHAL R, Swanton C, McGranahan N
    Understanding the impact of immune-mediated selection on lung cancer evolution.
    Br J Cancer. 2021 Feb 24. pii: 10.1038/s41416-020-01232.
    PubMed     Abstract available


    January 2021
  4. SURAWEERA A, Duff A, Adams MN, Jekimovs C, et al
    Correction: Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer.
    Br J Cancer. 2021 Jan 26. pii: 10.1038/s41416-020-01242.
    PubMed    


    December 2020
  5. BRANCHER S, Stoer NC, Weiderpass E, Damhuis RAM, et al
    Metformin use and lung cancer survival: a population-based study in Norway.
    Br J Cancer. 2020 Dec 2. pii: 10.1038/s41416-020-01186.
    PubMed     Abstract available


  6. LINDNER DJ, Wildey G, Parker Y, Dowlati A, et al
    CBL0137 increases the targeting efficacy of Rovalpituzumab tesirine against tumour-initiating cells in small cell lung cancer.
    Br J Cancer. 2020 Dec 1. pii: 10.1038/s41416-020-01192.
    PubMed     Abstract available


  7. STOREY CL, Hanna GG, Greystoke A
    Practical implications to contemplate when considering radical therapy for stage III non-small-cell lung cancer.
    Br J Cancer. 2020;123.
    PubMed     Abstract available


  8. PATEL P, Alrifai D, McDonald F, Forster M, et al
    Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi(R), AstraZeneca UK Limited).
    Br J Cancer. 2020;123.
    PubMed     Abstract available


  9. CONIBEAR J
    Rationale for concurrent chemoradiotherapy for patients with stage III non-small-cell lung cancer.
    Br J Cancer. 2020;123.
    PubMed     Abstract available


  10. PAZ-ARES L
    Summary of 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'.
    Br J Cancer. 2020;123.
    PubMed    


  11. EVISON M
    The current treatment landscape in the UK for stage III NSCLC.
    Br J Cancer. 2020;123.
    PubMed     Abstract available


  12. PAZ-ARES L
    Foreword to 'The current status and future perspectives on the management of stage III NSCLC: a focus on unresectable cancer treatment paradigms'.
    Br J Cancer. 2020;123.
    PubMed    


  13. ZELLWEGER M, Gonzalez M
    Comment on: the myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:1833-1834.
    PubMed    


  14. MACBETH F, Fallowfield DL
    Reply to 'Comment on "The myth of pulmonary metastasectomy'".
    Br J Cancer. 2020;123:1835-1836.
    PubMed    


  15. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available


    November 2020
  16. KANG JH, Lee KH, Kim DW, Kim SW, et al
    A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer.
    Br J Cancer. 2020 Nov 16. pii: 10.1038/s41416-020-01055.
    PubMed     Abstract available


    October 2020
  17. YANG L, Zhou F, Zhuang Y, Liu Y, et al
    Acetyl-bufalin shows potent efficacy against non-small-cell lung cancer by targeting the CDK9/STAT3 signalling pathway.
    Br J Cancer. 2020 Oct 30. pii: 10.1038/s41416-020-01135.
    PubMed     Abstract available


  18. HANSEN MS, Licaj I, Braaten T, Lund E, et al
    The fraction of lung cancer attributable to smoking in the Norwegian Women and Cancer (NOWAC) Study.
    Br J Cancer. 2020 Oct 27. pii: 10.1038/s41416-020-01131.
    PubMed     Abstract available


  19. SIDDIQUI MA, Gollavilli PN, Ramesh V, Parma B, et al
    Thymidylate synthase drives the phenotypes of epithelial-to-mesenchymal transition in non-small cell lung cancer.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01095.
    PubMed     Abstract available


  20. CREELAN BC, Yeh TC, Kim SW, Nogami N, et al
    A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
    Br J Cancer. 2020 Oct 5. pii: 10.1038/s41416-020-01099.
    PubMed     Abstract available


  21. SONG X, Gong J, Zhang X, Feng X, et al
    Plasma-based early screening and monitoring of EGFR mutations in NSCLC patients by a 3-color digital PCR assay.
    Br J Cancer. 2020;123:1437-1444.
    PubMed     Abstract available


    September 2020
  22. KIM TW, Hong DW, Park JW, Hong SH, et al
    CB11, a novel purine-based PPAR ligand, overcomes radio-resistance by regulating ATM signalling and EMT in human non-small-cell lung cancer cells.
    Br J Cancer. 2020 Sep 22. pii: 10.1038/s41416-020-01088.
    PubMed     Abstract available


  23. AMBROISE G, Yu TT, Zhang B, Kacal M, et al
    Systematic analysis reveals a functional role for STAMBPL1 in the epithelial-mesenchymal transition process across multiple carcinomas.
    Br J Cancer. 2020;123:1164-1177.
    PubMed     Abstract available


  24. TRAN CHAU V, Liu W, Gerbe de Thore M, Meziani L, et al
    Differential therapeutic effects of PARP and ATR inhibition combined with radiotherapy in the treatment of subcutaneous versus orthotopic lung tumour models.
    Br J Cancer. 2020;123:762-771.
    PubMed     Abstract available


    August 2020
  25. MACBETH F, Fallowfield L
    The myth of pulmonary metastasectomy.
    Br J Cancer. 2020;123:499-500.
    PubMed     Abstract available


  26. LI PETRI G, El Hassouni B, Sciarrillo R, Funel N, et al
    Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds.
    Br J Cancer. 2020;123:644-656.
    PubMed     Abstract available


  27. KOSMIDIS C, Sardeli C, Zarogoulidis P, Hohenforst-Schmidt W, et al
    Producing the appropriate model and drug for intratumoural ablation.
    Br J Cancer. 2020;123:335-336.
    PubMed     Abstract available


  28. NIEMEIJER AN, Sahba S, Smit EF, Lissenberg-Witte BI, et al
    Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy.
    Br J Cancer. 2020;123:392-402.
    PubMed     Abstract available


    July 2020
  29. GOMES F, Wong M, Battisti NML, Kordbacheh T, et al
    Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper.
    Br J Cancer. 2020 Jul 22. pii: 10.1038/s41416-020-0986.
    PubMed     Abstract available


  30. LUANPITPONG S, Rodboon N, Samart P, Vinayanuwattikun C, et al
    A novel TRPM7/O-GlcNAc axis mediates tumour cell motility and metastasis by stabilising c-Myc and caveolin-1 in lung carcinoma.
    Br J Cancer. 2020 Jul 20. pii: 10.1038/s41416-020-0991.
    PubMed     Abstract available


  31. CHEUNG VTF, Gupta T, Olsson-Brown A, Subramanian S, et al
    Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
    Br J Cancer. 2020;123:207-215.
    PubMed     Abstract available


    June 2020
  32. CICCOLINI J, Benzekry S, Barlesi F
    Deciphering the response and resistance to immune-checkpoint inhibitors in lung cancer with artificial intelligence-based analysis: when PIONeeR meets QUANTIC.
    Br J Cancer. 2020 Jun 16. pii: 10.1038/s41416-020-0918.
    PubMed     Abstract available


  33. ALAM SK, Wang L, Ren Y, Hernandez CE, et al
    ASCL1-regulated DARPP-32 and t-DARPP stimulate small cell lung cancer growth and neuroendocrine tumour cell proliferation.
    Br J Cancer. 2020 Jun 5. pii: 10.1038/s41416-020-0923.
    PubMed     Abstract available


    May 2020
  34. ROSSI SM, Ryan BK, Kelly HM
    Evaluation of the activity of a chemo-ablative, thermoresponsive hydrogel in a murine xenograft model of lung cancer.
    Br J Cancer. 2020 May 27. pii: 10.1038/s41416-020-0904.
    PubMed     Abstract available


  35. HSIN IL, Chiu LY, Ou CC, Wu WJ, et al
    CD133 inhibition via autophagic degradation in pemetrexed-resistant lung cancer cells by GMI, a fungal immunomodulatory protein from Ganoderma microsporum.
    Br J Cancer. 2020 May 25. pii: 10.1038/s41416-020-0885.
    PubMed     Abstract available


  36. SURAWEERA A, Duff A, Adams MN, Jekimovs C, et al
    Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer.
    Br J Cancer. 2020 May 22. pii: 10.1038/s41416-020-0899.
    PubMed     Abstract available


  37. WELCH CA, Sweeting MJ, Lambert PC, Rutherford MJ, et al
    Impact on survival of modelling increased surgical resection rates in patients with non-small-cell lung cancer and cardiovascular comorbidities: a VICORI study.
    Br J Cancer. 2020 May 11. pii: 10.1038/s41416-020-0869.
    PubMed     Abstract available


  38. ZULATO E, Attili I, Pavan A, Nardo G, et al
    Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.
    Br J Cancer. 2020 May 7. pii: 10.1038/s41416-020-0833.
    PubMed     Abstract available


    April 2020
  39. GELSOMINO F, Tiseo M, Barbieri F, Riccardi F, et al
    Phase 2 study of NAB-paclitaxel in SensiTivE and refractory relapsed small cell lung cancer (SCLC) (NABSTER TRIAL).
    Br J Cancer. 2020 Apr 29. pii: 10.1038/s41416-020-0845.
    PubMed     Abstract available


  40. SAITO R, Miki Y, Abe T, Miyauchi E, et al
    11beta hydroxysteroid dehydrogenase 1: a new marker for predicting response to immune-checkpoint blockade therapy in non-small-cell lung carcinoma.
    Br J Cancer. 2020 Apr 27. pii: 10.1038/s41416-020-0837.
    PubMed     Abstract available


  41. JETTE NR, Radhamani S, Arthur G, Ye R, et al
    Correction: Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    Br J Cancer. 2020 Apr 17. pii: 10.1038/s41416-020-0841.
    PubMed     Abstract available


  42. DAI W, Wang G, Chwa J, Oh ME, et al
    Mitochondrial division inhibitor (mdivi-1) decreases oxidative metabolism in cancer.
    Br J Cancer. 2020;122:1288-1297.
    PubMed     Abstract available


  43. VAN GEEL RMJM, van Brummelen EMJ, Eskens FALM, Huijberts SCFA, et al
    Phase 1 study of the pan-HER inhibitor dacomitinib plus the MEK1/2 inhibitor PD-0325901 in patients with KRAS-mutation-positive colorectal, non-small-cell lung and pancreatic cancer.
    Br J Cancer. 2020;122:1166-1174.
    PubMed     Abstract available


    March 2020
  44. GRIDELLI C, Ciuleanu T, Domine M, Szczesna A, et al
    Clinical activity of a htert (vx-001) cancer vaccine as post-chemotherapy maintenance immunotherapy in patients with stage IV non-small cell lung cancer: final results of a randomised phase 2 clinical trial.
    Br J Cancer. 2020 Mar 25. pii: 10.1038/s41416-020-0785.
    PubMed     Abstract available


  45. JEON KH, Shin DW, Han K, Kim D, et al
    Female reproductive factors and the risk of lung cancer in postmenopausal women: a nationwide cohort study.
    Br J Cancer. 2020 Mar 17. pii: 10.1038/s41416-020-0789.
    PubMed     Abstract available


  46. SAITO Y, Takahashi T, Obata Y, Nishida T, et al
    TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naive and imatinib-resistant gastrointestinal stromal tumours.
    Br J Cancer. 2020;122:658-667.
    PubMed     Abstract available


  47. ZHANG Q, Ganapathy S, Avraham H, Nishioka T, et al
    Nicotine exposure potentiates lung tumorigenesis by perturbing cellular surveillance.
    Br J Cancer. 2020;122:904-911.
    PubMed     Abstract available


    February 2020
  48. KUEHL PJ, Tellez CS, Grimes MJ, March TH, et al
    5-Azacytidine inhaled dry powder formulation profoundly improves pharmacokinetics and efficacy for lung cancer therapy through genome reprogramming.
    Br J Cancer. 2020 Feb 27. pii: 10.1038/s41416-020-0765.
    PubMed     Abstract available


  49. GIATROMANOLAKI A, Harris AL, Banham AH, Contrafouris CA, et al
    Carbonic anhydrase 9 (CA9) expression in non-small-cell lung cancer: correlation with regulatory FOXP3+T-cell tumour stroma infiltration.
    Br J Cancer. 2020 Feb 18. pii: 10.1038/s41416-020-0756.
    PubMed     Abstract available


  50. ACHA-SAGREDO A, Uko B, Pantazi P, Bediaga NG, et al
    Long non-coding RNA dysregulation is a frequent event in non-small cell lung carcinoma pathogenesis.
    Br J Cancer. 2020 Feb 5. pii: 10.1038/s41416-020-0742.
    PubMed     Abstract available


  51. WATTENBERG MM, Asch D, Yu S, O'Dwyer PJ, et al
    Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
    Br J Cancer. 2020;122:333-339.
    PubMed     Abstract available


    January 2020
  52. URSO L, Cavallari I, Sharova E, Ciccarese F, et al
    Metabolic rewiring and redox alterations in malignant pleural mesothelioma.
    Br J Cancer. 2020;122:52-61.
    PubMed     Abstract available


    December 2019
  53. HOU P, Shi P, Jiang T, Yin H, et al
    DKC1 enhances angiogenesis by promoting HIF-1alpha transcription and facilitates metastasis in colorectal cancer.
    Br J Cancer. 2019 Dec 20. pii: 10.1038/s41416-019-0695.
    PubMed     Abstract available


  54. MCCUTCHAN G, Smits S, Ironmonger L, Slyne C, et al
    Evaluation of a national lung cancer symptom awareness campaign in Wales.
    Br J Cancer. 2019 Dec 16. pii: 10.1038/s41416-019-0676.
    PubMed     Abstract available


    November 2019
  55. PARK W, Mezquita L, Okabe N, Chae YK, et al
    Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer.
    Br J Cancer. 2019 Nov 25. pii: 10.1038/s41416-019-0643.
    PubMed     Abstract available


    September 2019
  56. LEONETTI A, Sharma S, Minari R, Perego P, et al
    Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.
    Br J Cancer. 2019 Sep 30. pii: 10.1038/s41416-019-0573.
    PubMed     Abstract available


  57. ZHAO J, Giri A, Zhu X, Shrubsole MJ, et al
    Calcium: magnesium intake ratio and colorectal carcinogenesis, results from the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2019 Sep 23. pii: 10.1038/s41416-019-0579.
    PubMed     Abstract available


  58. SCHREIBER LM, Urbiola C, Das K, Spiesschaert B, et al
    The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer.
    Br J Cancer. 2019 Sep 18. pii: 10.1038/s41416-019-0574.
    PubMed     Abstract available


  59. XU Y, Huang Z, Lu H, Yu X, et al
    Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study.
    Br J Cancer. 2019 Sep 16. pii: 10.1038/s41416-019-0583.
    PubMed     Abstract available


  60. JETTE NR, Radhamani S, Arthur G, Ye R, et al
    Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
    Br J Cancer. 2019 Sep 4. pii: 10.1038/s41416-019-0565.
    PubMed     Abstract available


    August 2019
  61. KORPHAISARN K, Morris V, Davis JS, Overman MJ, et al
    Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma.
    Br J Cancer. 2019 Aug 13. pii: 10.1038/s41416-019-0548.
    PubMed     Abstract available


  62. YONEDA K, Kuwata T, Kanayama M, Mori M, et al
    Alteration in tumoural PD-L1 expression and stromal CD8-positive tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy for non-small cell lung cancer.
    Br J Cancer. 2019 Aug 7. pii: 10.1038/s41416-019-0541.
    PubMed     Abstract available


    July 2019
  63. ELEZ E, Pericay C, Valladares-Ayerbes M, Bando I, et al
    A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients.
    Br J Cancer. 2019 Jul 31. pii: 10.1038/s41416-019-0537.
    PubMed     Abstract available


  64. LAHEURTE C, Dosset M, Vernerey D, Boullerot L, et al
    Distinct prognostic value of circulating anti-telomerase CD4(+) Th1 immunity and exhausted PD-1(+)/TIM-3(+) T cells in lung cancer.
    Br J Cancer. 2019 Jul 30. pii: 10.1038/s41416-019-0531.
    PubMed     Abstract available


  65. GROEN HJM, van der Heijden EHFM, Klinkenberg TJ, Biesma B, et al
    Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.
    Br J Cancer. 2019 Jul 24. pii: 10.1038/s41416-019-0533.
    PubMed     Abstract available


    June 2019
  66. MORGENSZTERN D, Rose M, Waqar SN, Morris J, et al
    RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer.
    Br J Cancer. 2019 Jun 24. pii: 10.1038/s41416-019-0504.
    PubMed     Abstract available


    May 2019
  67. SELLERS K, Allen TD, Bousamra M 2nd, Tan J, et al
    Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes.
    Br J Cancer. 2019 May 22. pii: 10.1038/s41416-019-0464.
    PubMed     Abstract available


    April 2019
  68. HEIM L, Kachler K, Siegmund R, Trufa DI, et al
    Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer.
    Br J Cancer. 2019 Apr 8. pii: 10.1038/s41416-019-0444.
    PubMed     Abstract available


    March 2019
  69. CREELAN BC, Gray JE, Tanvetyanon T, Chiappori AA, et al
    Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.
    Br J Cancer. 2019 Mar 18. pii: 10.1038/s41416-019-0428.
    PubMed     Abstract available


    February 2019
  70. WU SR, Lin CH, Shih HP, Ko CJ, et al
    HAI-2 as a novel inhibitor of plasmin represses lung cancer cell invasion and metastasis.
    Br J Cancer. 2019 Feb 15. pii: 10.1038/s41416-019-0400.
    PubMed     Abstract available


  71. KIM SH, Go SI, Song DH, Park SW, et al
    Prognostic impact of CD8 and programmed death-ligand 1 expression in patients with resectable non-small cell lung cancer.
    Br J Cancer. 2019 Feb 12. pii: 10.1038/s41416-019-0398.
    PubMed     Abstract available


  72. MAILLE E, Brosseau S, Hanoux V, Creveuil C, et al
    MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial.
    Br J Cancer. 2019;120:387-397.
    PubMed     Abstract available


    November 2018
  73. TSE LA, Lin X, Li W, Qiu H, et al
    Smoking cessation sharply reduced lung cancer mortality in a historical cohort of 3185 Chinese silicotic workers from 1981 to 2014.
    Br J Cancer. 2018 Nov 13. pii: 10.1038/s41416-018-0292.
    PubMed     Abstract available


  74. TIBALDI C, Camerini A, Tiseo M, Mazzoni F, et al
    Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
    Br J Cancer. 2018 Nov 8. pii: 10.1038/s41416-018-0307.
    PubMed     Abstract available


    October 2018
  75. PASSIGLIA F, Cappuzzo F, Alabiso O, Bettini AC, et al
    Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations.
    Br J Cancer. 2018 Oct 31. pii: 10.1038/s41416-018-0234.
    PubMed     Abstract available


  76. BECKWITT CH, Clark AM, Ma B, Whaley D, et al
    Statins attenuate outgrowth of breast cancer metastases.
    Br J Cancer. 2018;119:1094-1105.
    PubMed     Abstract available


    September 2018
  77. SASAKI T, Seto T, Yamanaka T, Kunitake N, et al
    A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L.
    Br J Cancer. 2018 Sep 12. pii: 10.1038/s41416-018-0243.
    PubMed     Abstract available


    August 2018
  78. EL-KHOURY V, Beland M, Schritz A, Kim SY, et al
    Identification of beta-arrestin-1 as a diagnostic biomarker in lung cancer.
    Br J Cancer. 2018 Aug 6. pii: 10.1038/s41416-018-0200.
    PubMed     Abstract available


    June 2018
  79. ZHENG R, Du M, Zhang B, Xin J, et al
    Body mass index (BMI) trajectories and risk of colorectal cancer in the PLCO cohort.
    Br J Cancer. 2018 Jun 6. pii: 10.1038/s41416-018-0121.
    PubMed     Abstract available


    May 2018
  80. ABOU FAYCAL C, Brambilla E, Agorreta J, Lepeltier N, et al
    The sVEGFR1-i13 splice variant regulates a beta1 integrin/VEGFR autocrine loop involved in the progression and the response to anti-angiogenic therapies of squamous cell lung carcinoma.
    Br J Cancer. 2018 May 24. pii: 10.1038/s41416-018-0128.
    PubMed     Abstract available


  81. GAO F, Alwhaibi A, Artham S, Verma A, et al
    Endothelial Akt1 loss promotes prostate cancer metastasis via beta-catenin-regulated tight-junction protein turnover.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0110.
    PubMed     Abstract available


    April 2018
  82. BINS S, Basak EA, El Bouazzaoui S, Koolen SLW, et al
    Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.
    Br J Cancer. 2018 Apr 26. pii: 10.1038/s41416-018-0074.
    PubMed     Abstract available


  83. DOHERTY JA, Grieshober L, Houck JR, Barnett MJ, et al
    Nested case-control study of telomere length and lung cancer risk among heavy smokers in the beta-Carotene and Retinol Efficacy Trial.
    Br J Cancer. 2018 Apr 19. pii: 10.1038/s41416-018-0075.
    PubMed     Abstract available


    March 2018
  84. GHOSH KM, Lee LH, Beckingsale TB, Gerrand CH, et al
    Indeterminate nodules in osteosarcoma: what's the follow-up?
    Br J Cancer. 2018;118:634-638.
    PubMed     Abstract available


  85. DI GIROLAMO C, Walters S, Gildea C, Benitez Majano S, et al
    Which patients are not included in the English Cancer Waiting Times monitoring dataset, 2009-2013? Implications for use of the data in research.
    Br J Cancer. 2018;118:733-737.
    PubMed     Abstract available


  86. DEL RE M, Marconcini R, Pasquini G, Rofi E, et al
    PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.
    Br J Cancer. 2018 Mar 6. pii: bjc20189. doi: 10.1038/bjc.2018.
    PubMed     Abstract available


    February 2018
  87. HAN B, Li K, Zhao Y, Li B, et al
    Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).
    Br J Cancer. 2018 Feb 13. pii: bjc2017478. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  88. YUZHALIN AE, Urbonas T, Silva MA, Muschel RJ, et al
    A core matrisome gene signature predicts cancer outcome.
    Br J Cancer. 2018;118:435-440.
    PubMed     Abstract available


    January 2018
  89. SUN JM, Lee KH, Kim BS, Kim HG, et al
    Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).
    Br J Cancer. 2018 Jan 30. pii: bjc2017465. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  90. ANTONIO M, Saldana J, Linares J, Ruffinelli JC, et al
    Geriatric assessment may help decision-making in elderly patients with inoperable, locally advanced non-small-cell lung cancer.
    Br J Cancer. 2018 Jan 30. pii: bjc2017455. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  91. GADGEEL S, Shaw AT, Barlesi F, Crino L, et al
    Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.
    Br J Cancer. 2018;118:38-42.
    PubMed     Abstract available


    November 2017
  92. NANJO S, Hata A, Okuda C, Kaji R, et al
    Standard-dose osimertinib for refractory leptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer.
    Br J Cancer. 2017 Nov 30. pii: bjc2017394. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    October 2017
  93. THALER J, Sigel C, Beasley MB, Wisnivesky J, et al
    Clinically significant mutations in HIV-infected patients with lung adenocarcinoma.
    Br J Cancer. 2017;117:1392-1395.
    PubMed     Abstract available


  94. O'SULLIVAN D, Dowling P, Joyce H, McAuley E, et al
    A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.
    Br J Cancer. 2017;117:1326-1335.
    PubMed     Abstract available


  95. NI Z, Yao C, Zhu X, Gong C, et al
    Ailanthone inhibits non-small cell lung cancer cell growth through repressing DNA replication via downregulating RPA1.
    Br J Cancer. 2017 Oct 12. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  96. VAHL JM, Friedrich J, Mittler S, Trump S, et al
    Interleukin-10-regulated tumour tolerance in non-small cell lung cancer.
    Br J Cancer. 2017 Oct 10. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  97. GABASA M, Ikemori R, Hilberg F, Reguart N, et al
    Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients.
    Br J Cancer. 2017;117:1128-1138.
    PubMed     Abstract available


    September 2017
  98. GREYSTOKE A, Steele N, Arkenau HT, Blackhall F, et al
    SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
    Br J Cancer. 2017;117:938-946.
    PubMed     Abstract available


  99. KOSHIARIS C, Aveyard P, Oke J, Ryan R, et al
    Smoking cessation and survival in lung, upper aero-digestive tract and bladder cancer: cohort study.
    Br J Cancer. 2017 Sep 12. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  100. KLIMOV S, Rida PC, Aleskandarany MA, Green AR, et al
    Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    Br J Cancer. 2017;117:826-834.
    PubMed     Abstract available


    August 2017
  101. LI M, Yang J, Zhou W, Ren Y, et al
    Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
    Br J Cancer. 2017 Aug 29. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  102. CALLAHAN CL, Schwartz K, Ruterbusch JJ, Shuch B, et al
    Leukocyte telomere length and renal cell carcinoma survival in two studies.
    Br J Cancer. 2017;117:752-755.
    PubMed     Abstract available


  103. ADLER NR, Wolfe R, Kelly JW, Haydon A, et al
    Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Br J Cancer. 2017 Aug 8. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  104. CIULEANU TE, Ahmed S, Kim JH, Mezger J, et al
    Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer.
    Br J Cancer. 2017 Aug 3. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    July 2017
  105. ALEXANDER M, Wolfe R, Ball D, Conron M, et al
    Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer.
    Br J Cancer. 2017 Jul 20. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  106. WINTHER-LARSEN A, Demuth C, Fledelius J, Madsen AT, et al
    Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients.
    Br J Cancer. 2017 Jul 6. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    June 2017
  107. WEISS GJ, Waypa J, Blaydorn L, Coats J, et al
    A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
    Br J Cancer. 2017;117:33-40.
    PubMed     Abstract available


  108. SAMARENDRA H, Jones K, Petrinic T, Silva MA, et al
    A meta-analysis of CXCL12 expression for cancer prognosis.
    Br J Cancer. 2017;117:124-135.
    PubMed     Abstract available


  109. CHERNYAVSKIY P, Edmondson EF, Weil MM, Little MP, et al
    High-energy particle beam and gamma radiation exposure, familial relatedness and cancer in mice.
    Br J Cancer. 2017;117:41-50.
    PubMed     Abstract available


  110. PEDERSEN AB, Horvath-Puho E, Ehrenstein V, Rorth M, et al
    Frozen shoulder and risk of cancer: a population-based cohort study.
    Br J Cancer. 2017;117:144-147.
    PubMed     Abstract available


  111. BARRERA L, Montes-Servin E, Hernandez-Martinez JM, Garcia-Vicente MLA, et al
    CD47 overexpression is associated with decreased neutrophil apoptosis/phagocytosis and poor prognosis in non-small-cell lung cancer patients.
    Br J Cancer. 2017 Jun 20. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  112. BAHLEDA R, Grilley-Olson JE, Govindan R, Barlesi F, et al
    Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
    Br J Cancer. 2017;116:1505-1512.
    PubMed     Abstract available


    May 2017
  113. KAZDAL D, Harms A, Endris V, Penzel R, et al
    Prevalence of somatic mitochondrial mutations and spatial distribution of mitochondria in non-small cell lung cancer.
    Br J Cancer. 2017 May 30. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


  114. KOINIS F, Agelaki S, Karavassilis V, Kentepozidis N, et al
    Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
    Br J Cancer. 2017 May 16. doi: 10.1038/bjc.2017.
    PubMed     Abstract available


    March 2017
  115. MACLEOD AK, Acosta-Jimenez L, Coates PJ, McMahon M, et al
    Aldo-keto reductases are biomarkers of NRF2 activity and are co-ordinately overexpressed in non-small cell lung cancer.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed    


  116. MURUGANANDAN S, Alfonso H, Franklin P, Shilkin K, et al
    Comparison of outcomes following a cytological or histological diagnosis of malignant mesothelioma.
    Br J Cancer. 2017;116:703-708.
    PubMed     Abstract available


  117. MALAPELLE U, Mayo de-Las-Casas C, Rocco D, Garzon M, et al
    Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Br J Cancer. 2017;116:802-810.
    PubMed     Abstract available


    January 2017
  118. BOUCHARD G, Therriault H, Geha S, Bujold R, et al
    Radiation-induced lung metastasis development is MT1-MMP-dependent in a triple-negative breast cancer mouse model.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


  119. WU YL, Sequist LV, Hu CP, Feng J, et al
    EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6.
    Br J Cancer. 2017;116:175-185.
    PubMed     Abstract available


  120. KIM H, Sung JY, Park EK, Kho S, et al
    Regulation of anoikis resistance by NADPH oxidase 4 and epidermal growth factor receptor.
    Br J Cancer. 2017;116:370-381.
    PubMed     Abstract available


    September 2016
  121. HUANG J, Mondul AM, Weinstein SJ, Koutros S, et al
    Serum metabolomic profiling of prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2016 Sep 27. doi: 10.1038/bjc.2016.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: